Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

EUROPACE Raises Remote Monitoring Profile
"Moving to a more continuous follow-up approach would have the tremendous advantages of enhancing patient safety, decreasing physician and nurse work load, and allowing health staff to focus on medical emergencies," urged Professor Angelo Auricchio, from the European Heart Rhythm Association (EHRA) and official spokesperson of the European Society of Cardiology (ESC), adding that such systems may have the additional advantage of being more cost effective for health care providers.

Pfizer's Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients With Rheumatoid Arthritis, New Phase 2 Studies Show
Pfizer announced today that data from two new mid-stage clinical studies of the company"s oral JAK-3 inhibitor, CP-690,550, showed statistically significant response versus placebo for patients with rheumatoid arthritis (RA). Data from these two Phase 2 trials and one ongoing open-label safety study are being presented this week at the 10th Annual Congress of the European League Against Rheumatism (EULAR). These results confirm findings from two previously reported Phase 2 studies in RA and have been used to support dose selection for Phase 3.
News of the day
Cytori's Celution(R) 700 System To Be Regulated As A Medical Device By U.S. FDA
Cytori Therapeutics (NASDAQ:CYTX) was informed by the U.S. Food and Drug Administration (FDA) that the Celution® 700 System will be regulated as a medical device under the Federal Food, Drug, and Cosmetic Act. This determination, in response to Cytori"s Request for Designation, clears the way for Cytori to compile and submit a marketing application to the FDA for the Celution® 700 System for use as a medical device in aesthetic body contouring and/or filling of soft tissue voids.
Diagnostics

Southampton Surgeons Honoured For Developing Keyhole Lung Cancer Surgery In The UK

Two Southampton surgeons who contributed to the development of keyhole surgery to treat early stage lung cancer have been internationally commended for their work. Consultant thoracic surgeons Khalid Amer and Ali Zamir Khan have spent the past four years developing a technique known as video-assisted thoracoscopic surgery (VATS) lobectomy at Southampton General Hospital. The process involves making three small skin incisions through which a camera and operating instruments are placed into the chest to enable the surgeon to remove the cancerous part of the lung. VATS lobectomy is an operation performed by only a minority of surgeons in the UK due to the intricate skills required. Whereas removing lymph nodes is practised by open operation in other UK thoracic units, the technique of removing lymph nodes by keyhole surgery was developed in Southampton. Mr Amer and Mr Khan have advocated use of this method as it reduces pain, hospital stay, overall recovery time and shortens the time needed to return to work. The surgeons also believe that VATS is the perfect option for patients of 80 years and above, proving just as safe for them as for younger patients. Survival rate among those who undergo keyhole is better than the rate for invasive surgery, with records showing 70% of patients living three years after their operation compared to a rate of around 64% for open surgery. The results of their study, which began in April 2005, have been presented in national and international conferences and recently published in the International Society for Minimally Invasive Surgery (ISMIS) journal Innovations. Mr Amer and Mr Khan also presented their findings to some of the world"s top medics at the ISMIS conference in California last month, where they both received awards for their involvement in the project. "Until now, many institutions have been afraid to fully adopt this modern way of performing surgery due to fears of the effectiveness and safety as a cancer operation, but long term results show it has the same - if not better - results, with many added advantages," Mr Khan said. Mr Amer said removing lymph nodes during VATS lobectomy proved to be safe and effective in understanding the stages of lung cancer. "Removing surrounding lymph nodes at the same time as removing the lung cancer provides us with the best and most accurate information to decide whether or not a patient needs to follow the surgery with chemotherapy to improve their chances of survival, and to predict how the patient is likely to progress." Southampton University

Tummy Tuck commented:

Thanks for this post. The lung cancer information on this post is quite relevant and this is the think I like the most about this page

25.04.2012


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009